Johnson & Johnson Q3 2026 Results: J&J Raises 2026 Guidance as OTTAVA, IMAAVY and RYBREVANT FASPRO Advance
ohnson & Johnson Q3 2026 Results: sales rose 5.9% to $25.4B, adjusted EPS hit $2.59 and 2026 guidance rose to $11.10 adjusted EPS at the midpoint.
IQVIA Veeva Clinical Operations Expansion: IQVIA Selects Veeva CTMS, eTMF, Study Startup and Site Connect as Enterprise Standards
IQVIA and Veeva Systems have expanded their partnership. IQVIA Veeva clinical operations now includes Veeva CTMS, eTMF, Study Startup and Site Connect as enterprise standard applications across IQVIA clinical development studies, extending the earlier EDC partnership.
Regeneron Pasatru (garetosmab-grts) Shows Zero New HO Lesions in Adult FOP Patients in OPTIMA Extension
Regeneron Pasatru (garetosmab-grts) showed no new heterotopic ossification lesions from week 56 to week 84 in adults with FOP. The OPTIMA extension data were presented at ASBMR on October 12, 2026.
Johnson & Johnson ICOTYDE (icotrokinra) Posts Two-Year Phase 3 Results in Adults and Adolescents With Plaque Psoriasis
Johnson & Johnson ICOTYDE (icotrokinra) reported two-year Phase 3 ICONIC-LEAD results at Fall Clinical Dermatology 2026. At Week 112, ≥72% of treated adults and adolescents with plaque psoriasis achieved PASI 90, with no new safety signals identified.
IQVIA Launches IQVIA Life Science Models at TechIQ 2026 to Help Life Sciences Companies Predict Clinical Trial Outcomes
IQVIA Life Science Models were introduced at TechIQ 2026 to help life sciences companies predict clinical trial outcomes. IQVIA reports that 85% of predictions across 50 trials and 270 endpoints were on target or clinically close.
Roche Tecentriq Colon Cancer Milestone: FDA Approves Tecentriq and Tecentriq Hybreza With Chemotherapy for Stage III dMMR Disease
The FDA has approved Tecentriq and Tecentriq Hybreza with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III dMMR colon cancer, based on the phase III ATOMIC trial.
Pfizer TUKYSA FDA Approval: Chemotherapy-Free Front-Line Maintenance Now Available for HER2+ Metastatic Breast Cancer
The FDA has approved Tecentriq and Tecentriq Hybreza with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III dMMR colon cancer, based on the phase III ATOMIC trial.
Novartis Rhapsido FDA Approval: Remibrutinib Becomes First Treatment for Symptomatic Dermographism
The Novartis Rhapsido FDA approval makes remibrutinib the first approved treatment for adults with symptomatic dermographism not controlled by H1 antihistamines. It builds on Rhapsido’s existing chronic spontaneous urticaria indication.
Lilly Indiana Manufacturing Investment of $4.5 Billion, Opens Dedicated Genetic Medicine Facility
Eli Lilly has committed an additional $4.5 billion across two manufacturing sites in Lebanon, Indiana, taking its total Indiana capital expansion commitments since 2020 to more than $21 billion. The investment also marks the opening of Lilly Lebanon Advanced Therapies, the company’s first dedicated genetic medicine manufacturing facility.
Charles River Rapid Cell Banking Programs Cut Production Timelines by 40% With NGS Characterization
Charles River Laboratories (NYSE: CRL) has introduced rapid cell banking programs that the company says cut cell bank production timelines by 40% against a 20-week industry standard. The offering pairs rapid microbiological and mycoplasma tests with NGS characterization through its iDTECT platform.